Anastrozole powder is used with other treatments, such as surgery or radiation, to treat early breast cancer in women who have experienced menopause (change of life; end of monthly menstrual periods). This medication is also used in women, who have experienced menopause, as a first treatment of breast cancer that has spread within the breast or to other areas of the body. This medication is also used to treat breast cancer in women whose breast cancer has worsened after taking tamoxifen (Nolvadex). Anastrozole powder is in a class of medications called nonsteroidal aromatase inhibitors. It works by decreasing the amount of estrogen the body makes. This can slow or stop the growth of many types of breast cancer cells that need estrogen to grow.
02 Anastrozole powder (120511-73-1) video
03 Anastrozole powder Base Information
|Half Life||About 50 hours|
|Application||Anastrozole powder can treat breast cancer.|
04 Anastrozole powder General Description
Anastrozole powder is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole powder decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.
Anastrozole powder may not work as well if you take it together with estrogen medication (such as hormone replacement therapy, estrogen creams, or birth control pills, injections, implants, skin patches, and vaginal rings).
Anastrozole powder may increase your risk of a stroke or blood clot. Call your doctor at once if you have sudden numbness or weakness, (especially on one side of the body), sudden severe headache, slurred speech, or problems with vision or balance.
05 Anastrozole powder (120511-73-1) History
Anastrozole powder(an as’ troe zole) is a nonsteroidal inhibitor of aromatase, the enzyme responsible for the conversion of testosterone to estrone (E1) and of androstenedione to estradiol (E2). Highest levels of aromatase are found in the ovary and placenta, which are the major sources of estrogen in premenopausal women. However, aromatase is also found in other tissues, such as liver, kidney, adrenals, brain, muscle and subcutaneous fat where it is also active in producing estrogens, although at low levels. These tissues are the major source of estrogen in postmenopausal women. Inhibitors of aromatase were developed to block the synthesis of estrogen in the peripheral tissues and, thus, as antiestrogen therapy of estrogen receptor positive breast cancer in postmenopausal women. The aromatase inhibitors in current use include letrozole, exemestane and anastrozole powder. Anastrozole powder is a nonsteroidal, specific aromatase inhibitor which has little or no effect on adrenal glucocorticoid or mineralocorticoid synthesis. Anastrozole powder was approved for use in postmenopausal women with breast cancer in the United States in 1995. Anastrozole powder is available in 1 mg tablets in generic forms and under the brand name Arimidex popwder. Its current indications are as adjuvant therapy in postmenopausal women with hormone responsive breast cancer, as first line therapy of locally invasive or metastatic estrogen receptor positive breast cancer in postmenopausal women, and as adjuvant therapy in postmenopausal women with advanced breast cancer not responsive to tamoxifen. It is typically given in single oral doses of 1 mg daily for up to five years. Common side effects include hot flashes, night sweats, fatigue, dizziness, headache, somnolence, abdominal discomfort, nausea, arthralgias, weight gain and rash. Uncommon, but potentially severe side effects include decrease in bone mineral density, increase in serum cholesterol and increased rate of cardiovascular events.
06 Anastrozole (120511-73-1) Mechanism Of Action
Hormones are chemical substances that are produced by glands in the body, which enter the bloodstream and can cause effects in other parts of the body. For example, the hormone testosterone is made in the testicles and is responsible for male characteristics such as deepening voice and increased body hair. The use of hormone therapy to treat cancer is based on the observation that cancer cell growth can partially depend on hormone binding to receptors on the cancer cell surface.
Hormone therapies can work through methods such as stopping the production of a certain hormone or interfering with hormone binding to the cancer cell receptor. The different types of hormone therapies are categorized by their function and/or the type of hormone that is affected.
Anastrozole powder is an aromatase inhibitor. This means it blocks the enzyme aromatase (found in the body’s muscle, skin, breast and fat), which is used to convert androgens (hormones produced by the adrenal glands) into estrogens. Tumor cells dependent on estrogens grow less when there is no estrogen.
07 Anastrozole (120511-73-1) Application
Anastrozole powder is a drug indicated in the treatment of breast cancer in post-menopausal women. It is used both in adjuvant therapy (i.e. following surgery) and in metastatic breast cancer. It decreases the amount of estrogens that the body makes. Anastrozole powder belongs in the class of drugs known as aromatase inhibitors.
08 Anastrozole (120511-73-1) More research
Anastrozole powder may not work as well if you take it together with an estrogen medication (such as hormone replacement therapy, estrogen creams, or birth control pills, injections, implants, skin patches, and vaginal rings). Before you start taking anastrozole powder, tell your doctor if you also take tamoxifen or estrogen.
Other drugs may interact with anastrozole powder, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell each of your health care providers about all medicines you use now and any medicine you start or stop using.
09 Anastrozole (120511-73-1) Document Download
10 Anastrozole (120511-73-1) Reference
- “anastrozole”. Chemical Entities of Biological Interest (ChEBI). European Molecular Biology Laboratory. Archived from the original on 2011-09-22. Retrieved 2011-08-14.
- Dukes, M. (1997). “The Relevance of Preclinical Models to the Treatment of Postmenopausal Breast Cancer”. Oncology. 54 (2): 6–10. doi:10.1159/000227748. ISSN 0030-2414.
- Simpson ER (September 2003). “Sources of estrogen and their importance”. J. Steroid Biochem. Mol. Biol. 86 (3–5): 225–30. doi:10.1016/S0960-0760(03)00360-1. PMID 14623515.
- 01. Overview
- 02. Anastrozole powder (120511-73-1) video
- 03. Anastrozole powder Base Information
- 04. Anastrozole powder General Description
- 05. Anastrozole powder (120511-73-1) History
- 06. Anastrozole (120511-73-1) Mechanism Of Action
- 07. Anastrozole (120511-73-1) Application
- 08. Anastrozole (120511-73-1) More research
- 09. Anastrozole (120511-73-1) Document Download
- 10. Anastrozole (120511-73-1) Reference